You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis
|
|---|---|
| Published in |
Annals of the Rheumatic Diseases, June 2016
|
| DOI | 10.1136/annrheumdis-2016-209133 |
| Pubmed ID | |
| URN |
urn:nbn:se:liu:diva-132060
|
| Authors |
M Yates, R A Watts, I M Bajema, M C Cid, B Crestani, T Hauser, B Hellmich, J U Holle, M Laudien, M A Little, R A Luqmani, A Mahr, P A Merkel, J Mills, J Mooney, M Segelmark, V Tesar, K Westman, A Vaglio, N Yalçındağ, D R Jayne, C Mukhtyar |
| Abstract |
In this article, the 2009 European League Against Rheumatism (EULAR) recommendations for the management of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) have been updated. The 2009 recommendations were on the management of primary small and medium vessel vasculitis. The 2015 update has been developed by an international task force representing EULAR, the European Renal Association and the European Vasculitis Society (EUVAS). The recommendations are based upon evidence from systematic literature reviews, as well as expert opinion where appropriate. The evidence presented was discussed and summarised by the experts in the course of a consensus-finding and voting process. Levels of evidence and grades of recommendations were derived and levels of agreement (strengths of recommendations) determined. In addition to the voting by the task force members, the relevance of the recommendations was assessed by an online voting survey among members of EUVAS. Fifteen recommendations were developed, covering general aspects, such as attaining remission and the need for shared decision making between clinicians and patients. More specific items relate to starting immunosuppressive therapy in combination with glucocorticoids to induce remission, followed by a period of remission maintenance; for remission induction in life-threatening or organ-threatening AAV, cyclophosphamide and rituximab are considered to have similar efficacy; plasma exchange which is recommended, where licensed, in the setting of rapidly progressive renal failure or severe diffuse pulmonary haemorrhage. These recommendations are intended for use by healthcare professionals, doctors in specialist training, medical students, pharmaceutical industries and drug regulatory organisations. |
X Demographics
The data shown below were collected from the profiles of 113 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 12 | 11% |
| United Kingdom | 8 | 7% |
| Mexico | 6 | 5% |
| India | 6 | 5% |
| Ecuador | 5 | 4% |
| Saudi Arabia | 4 | 4% |
| France | 4 | 4% |
| United States | 3 | 3% |
| Italy | 2 | 2% |
| Other | 22 | 19% |
| Unknown | 41 | 36% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 72 | 64% |
| Practitioners (doctors, other healthcare professionals) | 21 | 19% |
| Scientists | 14 | 12% |
| Science communicators (journalists, bloggers, editors) | 6 | 5% |
Mendeley readers
The data shown below were compiled from readership statistics for 898 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Japan | 2 | <1% |
| Colombia | 1 | <1% |
| Italy | 1 | <1% |
| Australia | 1 | <1% |
| Hong Kong | 1 | <1% |
| Spain | 1 | <1% |
| Brazil | 1 | <1% |
| Unknown | 890 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 134 | 15% |
| Researcher | 125 | 14% |
| Student > Postgraduate | 97 | 11% |
| Student > Ph. D. Student | 72 | 8% |
| Student > Master | 66 | 7% |
| Other | 213 | 24% |
| Unknown | 191 | 21% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 543 | 60% |
| Immunology and Microbiology | 23 | 3% |
| Nursing and Health Professions | 16 | 2% |
| Pharmacology, Toxicology and Pharmaceutical Science | 15 | 2% |
| Agricultural and Biological Sciences | 14 | 2% |
| Other | 63 | 7% |
| Unknown | 224 | 25% |
Attention Score in Context
This research output has an Altmetric Attention Score of 175. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 14 November 2023.
All research outputs
#233,849
of 26,017,215 outputs
Outputs from Annals of the Rheumatic Diseases
#87
of 7,902 outputs
Outputs of similar age
#4,601
of 374,691 outputs
Outputs of similar age from Annals of the Rheumatic Diseases
#3
of 122 outputs
Altmetric has tracked 26,017,215 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 7,902 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 14.4. This one has done particularly well, scoring higher than 98% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 374,691 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 98% of its contemporaries.
We're also able to compare this research output to 122 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 97% of its contemporaries.